What is HC Wainwright’s Forecast for WVE FY2028 Earnings?

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Stock analysts at HC Wainwright dropped their FY2028 earnings estimates for shares of WAVE Life Sciences in a note issued to investors on Tuesday, May 19th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.75) for the year, down from their previous forecast of ($0.74). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ FY2029 earnings at ($0.64) EPS and FY2030 earnings at ($0.43) EPS.

A number of other analysts also recently commented on WVE. Cantor Fitzgerald boosted their price objective on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Wall Street Zen raised shares of WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a report on Saturday, May 2nd. Citigroup reduced their price target on shares of WAVE Life Sciences from $30.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, May 4th. Mizuho upped their price target on shares of WAVE Life Sciences from $22.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Finally, Wedbush upped their price target on shares of WAVE Life Sciences from $33.00 to $35.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $27.25.

WAVE Life Sciences Trading Up 0.8%

WVE stock opened at $6.19 on Thursday. The company has a market cap of $1.19 billion, a P/E ratio of -5.84 and a beta of -1.32. WAVE Life Sciences has a 52 week low of $5.02 and a 52 week high of $21.73. The company’s 50-day moving average price is $8.37 and its 200 day moving average price is $11.19.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.21. The company had revenue of $38.25 million for the quarter, compared to analyst estimates of $8.45 million. WAVE Life Sciences had a negative net margin of 255.70% and a negative return on equity of 56.76%.

Insider Activity

In other WAVE Life Sciences news, insider Chris Francis sold 33,194 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $15.05, for a total value of $499,569.70. Following the sale, the insider owned 61,867 shares of the company’s stock, valued at $931,098.35. This represents a 34.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 24.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On WAVE Life Sciences

A number of institutional investors have recently modified their holdings of WVE. Federated Hermes Inc. boosted its stake in shares of WAVE Life Sciences by 678,144.7% in the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock valued at $27,455,000 after purchasing an additional 3,750,140 shares during the period. Pictet Asset Management Holding SA boosted its stake in shares of WAVE Life Sciences by 5,024.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 805,901 shares of the company’s stock valued at $13,830,000 after purchasing an additional 790,175 shares during the period. GSA Capital Partners LLP purchased a new position in shares of WAVE Life Sciences in the third quarter valued at $375,000. F m Investments LLC boosted its stake in WAVE Life Sciences by 24.5% during the 4th quarter. F m Investments LLC now owns 395,894 shares of the company’s stock valued at $6,730,000 after acquiring an additional 77,807 shares during the last quarter. Finally, Knott David M Jr boosted its stake in WAVE Life Sciences by 125.0% during the 3rd quarter. Knott David M Jr now owns 90,000 shares of the company’s stock valued at $659,000 after acquiring an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.